Search Results
Aug 16, 2026, 20:00 ET AbelZeta Regains Global Rights of C-CAR039 (Prizlon-cel) and Receives FDA Clearance of IND Application in Large B-cell Lymphoma
treatment naïve.The program is supported by encouraging long-term clinical data presented at European Society for Blood and Marrow Transplantation (EBMT) in March 2026. Results from 48 patients with r/r B-cell non-Hodgkin lymphoma (B-NHL) enrolled in the Company's early clinical trials in China demonstrated
More news about: AbelZeta Pharma, Inc.
Mar 10, 2026, 07:02 ET Zemcelpro® (dorocubicel) Positive Results in High- and Very High-Risk Blood Cancers to be Reported at the EBMT 2026 Annual Meeting
leukemias and myelodysplastic syndromes Topline results from two Phase 2 studies to be presented on March 23, 2026 at the EBMT Annual Meeting in Madrid, SpainMONTREAL, March 10, 2026 /PRNewswire/
More news about: ExCellThera
Mar 10, 2026, 07:02 ET Zemcelpro® (dorocubicel) Positive Results in High- and Very High-Risk Blood Cancers to be Reported at the EBMT 2026 Annual Meeting
leukemias and myelodysplastic syndromes Topline results from two Phase 2 studies to be presented on March 23, 2026 at the EBMT Annual Meeting in Madrid, SpainMONTREAL, March 10, 2026 /PRNewswire/
More news about: ExCellThera
Oct 28, 2025, 17:31 ET CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight
retrospective study of brexucabtagene autoleucel in patients over 70 years of age with R/R MCL who do not benefit from intensive treatment at the 51st Annual EBMT Meeting. In February 2025, Miltenyi Biomedicine presented the data from the Phase II DALY II USA trial (NCT04792489)
More news about: DelveInsight Business Research, LLP